Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related .
International Association for the Study of Lung CancerJanuary 29, 2021 GMT
SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) Several leading international lung cancer researchers at a press today presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC’s World Conference on Lung Cancer 2020 Singapore.
(Note: you may access a recording of the press briefing at this link: https://vimeo.com/505823998/d5260e13a9 )
Immunoscape forms scientific advisory board of distinguished immunology experts 29 Jan 2021 / 19:30 H. Pix for representational purpose only.
KUALA LUMPUR: Biotech company, ImmunoScape has announced the formation of its Scientific Advisory Board (SAB) comprising leading scientists in immunology and oncology who will help to guide ImmunoScape’s scientific strategy.
The founding members of the SAB bring substantial scientific insight and expertise to assist the company, which include Evan Newell, Ph.D.; Philip Greenberg, M.D.; Patrick Reeves, Ph.D.; and, Paul Thomas, Ph.D.
“To form this scientific advisory board, we brought together key thought leaders within immunology, across academia and industry alike,” said ImmunoScape Director of Scientific Affairs, Michael Fehlings, Ph.D. in a statement.
International Association for
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related Factors that Create Disparities
Lung Cancer Care and Research Not Immune to Socioeconomic, Ethnic, Racial, and Gender-related Factors that Create Disparities
Press Briefing at IASLC World Conference on Lung Cancer 2020 Singapore
SINGAPORE, Jan. 28, 2021 (GLOBE NEWSWIRE) Several leading international lung cancer researchers at a press today presented compelling new data revealing that factors of race, gender, sexual orientation and income continue to be significant barriers to those living with lung cancer. The press briefing is part of the IASLC’s World Conference on Lung Cancer 2020 Singapore.
A syringe is filled with Moderna s COVID-19 vaccine at University Hospital Magdeburg.
PHOTO: RONNY HARTMANN/AFP/GETTY IMAGES
News from U.S. manufacturer Moderna that its COVID-19 vaccine is still “expected to be protective” against a virus variant first detected in South Africa came as a relief to scientists and the public. But the 25 January announcement included a caveat: Antibodies triggered by the vaccine appear to be a little less potent against the new variant, named B.1.351, than the one the vaccine was developed for. So researchers were perhaps even more relieved to hear the company will start development of booster shots tailored to B.1.351 and other variants.